Patients with multiple sclerosis receiving chronic ocrelizumab treatment may develop hypogammaglobulinemia and experience ...
Tocilizumab may offer more consistent relapse suppression than rituximab in MOGAD, though pooled estimates do not establish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results